NASDAQ:ARTV Artiva Biotherapeutics Q3 2026 Earnings Date & Estimates $4.27 -1.89 (-30.68%) Closing price 10/27/2026 04:00 PM EasternExtended Trading$4.22 -0.05 (-1.08%) As of 05:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Artiva Biotherapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 11, 2026Conference Call DateNovember 12, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Artiva Biotherapeutics in Q3 2026Artiva Biotherapeutics is expected to post earnings of -$0.54 per share. In the same quarter a year earlier Artiva Biotherapeutics reported -$0.88 per share. Artiva Biotherapeutics last reported on August 6, 2026, posting -$0.63 per share and missing the -$0.6251 consensus estimate. Artiva Biotherapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.54Prior-Year EPS-$0.88Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.63 (Missed by -$0.0049)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Artiva Biotherapeutics Q3 2026 Earnings FAQ When does Artiva Biotherapeutics report Q3 2026 earnings? Artiva Biotherapeutics (NASDAQ:ARTV) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Artiva Biotherapeutics' Q3 2026 earnings call? Artiva Biotherapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Artiva Biotherapeutics? Analysts expect Artiva Biotherapeutics to post earnings of -$0.54 per share for Q3 2026. Artiva Biotherapeutics Earnings HeadlinesArtiva Biotherapeutics Shares Fall After Announcing Plan to End AlloNK Development, Analyst DowngradesOctober 27 at 10:54 PM | finance.yahoo.comArtiva Biotherapeutics Discontinues Development of AlloNKOctober 27 at 5:54 PM | marketscreener.comMDO YOU LIVE HERE? ⬇️Data centers now number about 1,300 across the US, with another 2,500 planned. Each can draw as much power as 100,000 homes, and one Virginia homeowner saw his bill jump from $100 to $281 in a single month. Elon Musk has filed a plan with the FCC to move data centers out of cities entirely, a move backed by President Trump. One lesser-known, publicly traded company trading under $100 a share may sit at the center of that shift. | Paradigm Press (Ad)Why is Artiva Biotherapeutics discontinuing AlloNK development and cutting 94% of its workforce?October 27 at 5:54 PM | msn.comArtiva discontinues cell therapy after two patient deaths, cuts workforce by 94%October 27 at 12:53 PM | reuters.comArtiva Biotherapeutics stock tumbles after halting drug trialOctober 27 at 12:53 PM | finance.yahoo.comSee More Artiva Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Artiva Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Artiva Biotherapeutics and other key companies, straight to your email. Email Address About Artiva BiotherapeuticsArtiva Biotherapeutics (NASDAQ:ARTV) is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells. Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases. Its technology platform is designed to support the expansion, cryopreservation and scalable production of NK cells for potential use across multiple indications. Artiva was founded to advance allogeneic NK cell therapies and is headquartered in San Diego, California. Its development activities have focused primarily on clinical programs in the United States. The company is led by co-founder and Chief Executive Officer Fred Aslan.View Artiva Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple's Foldable iPhone Sold Out in Minutes, But Wall Street Has QuestionsCoca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest StrengthWhirlpool's Stock Collapse Raises a Bigger Question About Its Recovery PotentialAnalysts Turn Bullish on Meta Platforms Despite Post-Earnings FallLockheed Martin's F-35 Deal Could Change How Wall Street Values the StockIntel's $155 Price Target Raises a Bigger Question About Its Turnaround PotentialMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid? Upcoming Earnings Starbucks (10/29/2026)Amazon.com (10/29/2026)Anheuser-Busch InBev SA/NV (10/29/2026)Mondelez International (10/29/2026)Altria Group (10/29/2026)Cheniere Energy (10/29/2026)TotalEnergies (10/29/2026)Republic Services (10/29/2026)CRH (10/29/2026)BP (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
